Kala Pharmaceuticals promotes Todd Bazemore to President and COO, effective Dec 16, 2021

KALA BIO, Inc.

Todd Bazemore, COO since Nov 2017, appointed President and COO effective December 16, 2021.
Mark Iwicki remains CEO and Chairman but no longer serves as President of the Company.
No changes to Bazemore's compensation or compensatory plans in connection with the promotion.
Bazemore has served on Pulmatrix's board of directors since October 2020.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Mark Iwicki

President

KALA · KALA BIO, Inc.

Effective: 2021-12-16
Successor: Todd Bazemore
Filed: December 20, 2021, 6:59 PM ET

Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.

Role change

Todd Bazemore

President and Chief Operating Officer

KALA · KALA BIO, Inc.

Effective: 2021-12-16
Filed: December 20, 2021, 6:59 PM ET

On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the “Company”) appointed Todd Bazemore, the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Operating Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Iwicki changed role as President at KALA BIO, Inc..

Action: will no longer serve as
Role: President

Exact text from the filing

Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Todd Bazemore was appointed as President and Chief Operating Officer at KALA BIO, Inc..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the “Company”) appointed Todd Bazemore, the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Operating Officer, effective immediately.

View on SEC.gov

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-21-016940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.